Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428077 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00428077 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT00428077, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.
Interventions
- GENETIC reverse transcriptase-polymerase chain reaction
- BIOLOGICAL bcr-abl peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428077
The ClinicalTrials.gov registry entry for NCT00428077 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which reverse transcriptase-polymerase chain reaction is the first listed.
NCT00428077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428077 about?
NCT00428077 is a clinical study titled "Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.
What is the current status of trial NCT00428077?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2005-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00428077?
The interventions under investigation include: reverse transcriptase-polymerase chain reaction (GENETIC), bcr-abl peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00428077?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.